-
Multi- and poly-pharmacology of carbonic anhydrase inhibitors. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-26 Claudiu T Supuran
Eight genetically distinct families of the enzyme carbonic anhydrase (CA, EC 4.2.1.1) were described in organisms allover the phylogenetic tree. They catalyze the hydration of CO2 to bicarbonate and protons, and are involved in pH regulation, chemosensing and metabolism. The 15 α-CA isoforms present in humans are pharmacological drug targets known for decades, their inhibitors being used as diuretics
-
Prospects for the convergence of polyphenols with pharmaceutical drugs in Type 2 Diabetes: challenges, risks, and strategies. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-26 S Allamreddy,M Arora,R Ganugula,R Friend,R Basu,M N V Ravi Kumar
Type 2 diabetes mellitus (T2DM) is a complex disease that can lead to a variety of life-threatening secondary health conditions. Current treatment strategies primarily revolve around tight glucose control that is difficult to achieve and often turns out to be dangerous due to possible hypoglycemic events. Numerous long-term studies have demonstrated that complex pathways, including low-grade inflammation
-
Emerging Pharmacotherapies for Obesity: A Systematic Review. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-20 Michail Kokkorakis,Marlene Chakhtoura,Caline Rhayem,Jana Al Rifai,Malak Ghezzawi,Laura Valenzuela-Vallejo,Christos S Mantzoros
The history of anti-obesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the conviction that excess body weight signifies a lack of willpower. However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the
-
Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-20 Ana Pocivavsek,Robert Schwarcz,Sophie Erhardt
Both pre-clinical and clinical studies implicate functional impairments of several neuroactive metabolites of the kynurenine pathway (KP), the major degradative cascade of the essential amino acid tryptophan in mammals, in the pathophysiology of neurological and psychiatric diseases. A number of KP enzymes, such as tryptophan 2,3-dioxygenase (TDO2), indoleamine 2,3-dioxygenases (IDO1 and IDO2), kynurenine
-
International Union of Basic and Clinical Pharmacology. CXVII: Taste 2 receptors: Structures, functions, activators and blockers. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-08-30 Maik Behrens
Bitter perception plays a critical role for the detection of potentially harmful substances in food items for most vertebrates. The detection of bitter compounds is facilitated by specialized receptors located in taste buds of the oral cavity. This work focuses on the receptors, including their sensitivities, structure-function relationships, agonists and antagonists. Moreover, the existence of numerous
-
Intestinal Lymphatic Biology, Drug Delivery and Therapeutics: Current status and Future directions. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-08-23 Sanjeevini Babu Reddiar,Yining Xie,Mohammad Abdallah,Sifei Han,Luojuan Hu,Orlagh M Feeney,Gracia Gracia,Abel Anshabo,Zijun Lu,Muhammad Asim Farooq,Ian K Styles,Anthony Rj Phillips,John A Windsor,Christopher Jh Porter,Enyuan Cao,Natalie L Trevaskis
Historically, the intestinal lymphatics were considered passive conduits for fluids, immune cells, dietary lipids, lipid soluble vitamins and lipophilic drugs. Studies of intestinal lymphatic drug delivery in the late 20th century focussed primarily on the drug physicochemical properties, especially high lipophilicity, that resulted in intestinal lymphatic transport. More recent discoveries have changed
-
Post-translational Modifications of α-Synuclein, their Therapeutic Potential and Crosstalk in Health and Neurodegenerative Diseases. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-08-20 Kambiz Hassanzadeh,Jun Liu,Santhosh Maddila,M Maral Mouradian
α-Synuclein (α-Syn) aggregation in Lewy bodies and Lewy neurites has emerged as a key pathogenetic feature in Parkinson's disease (PD), Dementia with Lewy Bodies and Multiple System Atrophy. Various factors, including post-translational modifications (PTMs), can influence the propensity of α-Syn to misfold and aggregate. PTMs are biochemical modifications of a protein that occur during or after translation
-
Intestinal Barrier, Immunity and Microbiome: Partners in the Depression Crime Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Eva M. Medina-Rodríguez, José Martínez-Raga, Yolanda Sanz, Habibeh Khoshbouei
-
The Development of Cannabinoids as Therapeutic Agents in the United States Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Conor H. Murray, Brenda M. Gannon, Peter J. Winsauer, Ziva D. Cooper, Marcus S. Delatte, Matthew Banks
Cannabis is one of the oldest and widely used substances in the world. Cannabinoids within the cannabis plant, known as phytocannabinoids, mediate cannabis’ effects through interactions with the body’s endogenous cannabinoid system. This endogenous system, the endocannabinoid system, has important roles in physical and mental health. These roles point to the potential to develop cannabinoids as therapeutic
-
The Art of Finding the Right Drug Target: Emerging Methods and Strategies Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Zi-Chang Jia, Xue Yang, Yi-Kun Wu, Min Li, Debatosh Das, Mo-Xian Chen, Jian Wu, Martin Michel
Drug targets are specific molecules in biological tissues and body fluids that interact with drugs. Drug target discovery is a key component of drug discovery and is essential for the development of new drugs in areas such as cancer therapy and precision medicine. Traditional in vitro or in vivo target discovery methods are time-consuming and labor-intensive, limiting the pace of drug discovery. With
-
Pharmacology of Hydrogen Sulfide and Its Donors in Cardiometabolic Diseases Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Hai-Jian Sun, Qing-Bo Lu, Xue-Xue Zhu, Zhang-Rong Ni, Jia-Bao Su, Xiao Fu, Guo Chen, Guan-Li Zheng, Xiao-Wei Nie, Jin-Song Bian, Richard Ye
Cardiometabolic diseases (CMDs) are major contributors to global mortality, emphasizing the critical need for novel therapeutic interventions. Hydrogen sulfide (H2S) has garnered enormous attention as a significant gasotransmitter with various physiological, pathophysiological, and pharmacological impacts within mammalian cardiometabolic systems. In addition to its roles in attenuating oxidative stress
-
Conotoxins Targeting Voltage-Gated Sodium Ion Channels Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Shengrong Pei, Nan Wang, Zaoli Mei, Dongting Zhangsun, David J. Craik, J. Michael McIntosh, Xiaopeng Zhu, Sulan Luo, Thomas Gudermann
-
Cardiovascular Pharmacogenetics: From Discovery of Genetic Association to Clinical Adoption of Derived Test Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Benoît Delabays, Katerina Trajanoska, Joshua Walonoski, Vincent Mooser, Rhian Touyz
-
Topically Applied Therapies for the Treatment of Skin Disease: Past, Present, and Future Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Marc Brown, Adrian Williams, Robert P. Chilcott, Brendan Brady, Jon Lenn, Charles Evans, Lynn Allen, William J. McAuley, Mubinah Beebeejaun, Jasmin Haslinger, Claire Beuttel, Raquel Vieira, Florencia Guidali, Margarida Miranda, Clive Page
The purpose of this review is to summarize essential biological, pharmaceutical, and clinical aspects in the field of topically applied medicines that may help scientists when trying to develop new topical medicines. After a brief history of topical drug delivery, a review of the structure and function of the skin and routes of drug absorption and their limitations is provided. The most prevalent diseases
-
International Union of Basic and Clinical Pharmacology CXIV: Orexin Receptor Function, Nomenclature and Pharmacology Pharmacol. Rev. (IF 19.3) Pub Date : 2024-09-01 Jyrki. P. Kukkonen, Laura H. Jacobson, Daniel Hoyer, Maiju K. Rinne, Stephanie L. Borgland, Eliot Ohlstein
-
International Union of Basic and Clinical Pharmacology. CXVI: NC-IUPHAR and Pharmacological Reviews: 30+ Years of Collaboration-Editorial. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-08-15 Eliot H Ohlstein
-
The Enduring Impact of Pharmacological Reviews-Editorial. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-08-15 David R Sibley
-
Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-07-25 F Peter Guengerich
Our knowledge of the roles of individual cytochrome P450 (P450, CYP) enzymes in drug metabolism has developed considerably in the past 30 years, and this base has been of considerable use in avoiding serious issues with drug interactions and issues due to variations. Some newer approaches are being considered for "phenotyping" of metabolism reactions with new drug candidates. Endogenous biomarkers
-
Somatostatin: Linking Cognition and Alzheimer's Disease to Therapeutic Targeting. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-07-16 Karin E Sandoval,Ken A Witt
Over four decades of research support the link between Alzheimer's disease (AD) and somatostatin (somatotropin-releasing inhibitory factor, SRIF). SRIF and SRIF-expressing neurons play an essential role in brain function, modulating hippocampal activity and memory formation. Loss of SRIF and SRIF-expressing neurons in the brain rests at the center of a series of interdependent pathological events driven
-
Drug-drug interactions and synergy: from pharmacological models to clinical application. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-07-15 Luigino Calzetta,Clive Page,Maria Gabriella Matera,Mario Cazzola,Paola Rogliani
This review explores the concept of synergy in pharmacology, emphasizing its importance in optimizing treatment outcomes through the combination of drugs with different mechanisms of action. Synergy, defined as an effect greater than the expected additive effect elicited by individual agents according to specific predictive models, offers a promising approach to enhance therapeutic efficacy while minimizing
-
Bile acid signaling in metabolic and inflammatory diseases and drug development. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-07-08 Tiangang Li,John Y L Chiang
Bile acids are the end products of cholesterol catabolism. Hepatic bile acid synthesis accounts for a major fraction of daily cholesterol turnover in humans. Biliary secretion of bile acids generates bile flow and facilitates biliary secretion of lipids, endogenous metabolites and xenobiotics. In intestine, bile acids facilitate the digestion and absorption of dietary lipids and fat-soluble vitamins
-
International Union of Basic and Clinical Pharmacology. CXV: The Class F of G Protein-Coupled Receptors. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-07-02 Gunnar Schulte
The class F of G protein-coupled receptors (GPCRs) consists of ten Frizzleds (FZD1-10) and Smoothened (SMO). FZDs bind and are activated by secreted lipoglycoproteins of the Wingless/Int-1 (WNT) family and SMO is indirectly activated by the Hedgehog (Hh) family of morphogens acting on the transmembrane protein Patched (PTCH). The advance of our understanding of FZDs and SMO as dynamic transmembrane
-
Generation of Comprehensive GPCR-Transducer-Deficient Cell Lines to Dissect the Complexity of GPCR Signaling Pharmacol. Rev. (IF 19.3) Pub Date : 2024-07-01 Ayaki Saito, Ryoji Kise, Asuka Inoue, Gunnar Schulte
G-protein–coupled receptors (GPCRs) compose the largest family of transmembrane receptors and are targets of approximately one-third of Food and Drug Administration–approved drugs owing to their involvement in almost all physiologic processes. GPCR signaling occurs through the activation of heterotrimeric G-protein complexes and β-arrestins, both of which serve as transducers, resulting in distinct
-
Precision Medicine in Rheumatic Diseases: Unlocking the Potential of Antibody-Drug Conjugates Pharmacol. Rev. (IF 19.3) Pub Date : 2024-07-01 Zhiwen Huang, Zachary Braunstein, Jun Chen, Yingying Wei, Xiaoquan Rao, Lingli Dong, Jixin Zhong, Clive Page
-
Novel and Emerging Treatments to Target Pathophysiological Mechanisms in Various Phenotypes of Multiple Sclerosis Pharmacol. Rev. (IF 19.3) Pub Date : 2024-07-01 Gabriel Bsteh, Assunta Dal Bianco, Tobias Zrzavy, Thomas Berger, Harald Sitte
The objective is to comprehensively review novel pharmacotherapies used in multiple sclerosis (MS) and the possibilities they may carry for therapeutic improvement. Specifically, we discuss pathophysiological mechanisms worth targeting in MS, ranging from well known targets, such as autoinflammation and demyelination, to more novel and advanced targets, such as neuroaxonal damage and repair. To set
-
Hope on the Horizon: Promising Therapies for Steatotic Liver Disease Pharmacol. Rev. (IF 19.3) Pub Date : 2024-07-01 Amirhossein Sahebkar, Ali H. Eid
Steatotic liver disease (SLD) is a highly prevalent chronic liver disease with significant challenges for global health. The pathophysiology of SLD involves an interplay among genetic, endocrine, and metabolic factors. Successful management of SLD entails accurate diagnosis and disease monitoring through noninvasive methods such as advanced imaging techniques and biomarkers. Many emerging pharmacotherapies
-
Pharmacology and Precision Medicine-Preparing for the Next Era in Clinical Medicine-Editorial. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-06-14 Rhian M Touyz
-
Nitric Oxide Signaling and Regulation in the Cardiovascular System: Recent Advances. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-06-12 Mattias Carlstrom,Eddie Weitzberg,Jon O Lundberg
Nitric oxide (NO) from endothelial NO synthase (eNOS) importantly contributes to vascular homeostasis. Reduced NO production or increased scavenging during disease conditions with oxidative stress contribute to endothelial dysfunction and NO deficiency. In addition to the classical enzymatic NOS system, NO can also be generated via the nitrate-nitrite-NO pathway. Dietary and pharmacological approaches
-
Molecular Pathways Governing the Termination of Liver Regeneration Pharmacol. Rev. (IF 19.3) Pub Date : 2024-05-01 Lianne R. de Haan, Rowan F. van Golen, Michal Heger, Martin Michel
-
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies Pharmacol. Rev. (IF 19.3) Pub Date : 2024-05-01 Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros, Ali Eid
-
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future Pharmacol. Rev. (IF 19.3) Pub Date : 2024-05-01 Wei Wang, Najah Albadari, Yi Du, Josef F. Fowler, Hannah T. Sang, Wa Xian, Frank McKeon, Wei Li, Jia Zhou, Ruiwen Zhang, Michael Gottesman
-
Prostaglandin E2 in the Tumor Microenvironment, a Convoluted Affair Mediated by EP Receptors 2 and 4 Pharmacol. Rev. (IF 19.3) Pub Date : 2024-05-01 Ana Santiso, Akos Heinemann, Julia Kargl, Michael Gottesman
-
Adrenoceptor Desensitization: Current Understanding of Mechanisms Pharmacol. Rev. (IF 19.3) Pub Date : 2024-05-01 Dina Maaliki, Aneese A. Jaffa, Suzanne Nasser, Amirhossein Sahebkar, Ali H. Eid, Paul Insel, Martin Michel
G-protein coupled receptors (GPCRs) transduce a wide range of extracellular signals. They are key players in the majority of biologic functions including vision, olfaction, chemotaxis, and immunity. However, as essential as most of them are to body function and homeostasis, overactivation of GPCRs has been implicated in many pathologic diseases such as cancer, asthma, and heart failure (HF). Therefore
-
New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview Pharmacol. Rev. (IF 19.3) Pub Date : 2024-05-01 Analia Bortolozzi, Giovanna Fico, Michael Berk, Marco Solmi, Michele Fornaro, Joao Quevedo, Carlos A. Zarate, Lars V. Kessing, Eduard Vieta, Andre F. Carvalho, Robert Dantzer
Over the last six decades, lithium has been considered the gold standard treatment for the long-term management of bipolar disorder due to its efficacy in preventing both manic and depressive episodes as well as suicidal behaviors. Nevertheless, despite numerous observed effects on various cellular pathways and biologic systems, the precise mechanism through which lithium stabilizes mood remains elusive
-
A Chance to Grow and Excel as an Associate Editor of Pharmacological Reviews-Editorial. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-05-02 Ali H Eid
-
The Arylamine N-Acetyltransferases as Therapeutic Targets in Metabolic Diseases Associated with Mitochondrial Dysfunction Pharmacol. Rev. (IF 19.3) Pub Date : 2024-03-01 Chandra Choudhury, Melinder K. Gill, Courtney E. McAleese, Neville J. Butcher, Shyuan T. Ngo, Frederik J. Steyn, Rodney F. Minchin, Michael Gottesman
In humans, there are two arylamine N-acetyltransferase genes that encode functional enzymes (NAT1 and NAT2) as well as one pseudogene, all of which are located together on chromosome 8. Although they were first identified by their role in the acetylation of drugs and other xenobiotics, recent studies have shown strong associations for both enzymes in a variety of diseases, including cancer, cardiovascular
-
The Role of G Protein-Coupled Receptors and Receptor Kinases in Pancreatic {beta}-Cell Function and Diabetes Pharmacol. Rev. (IF 19.3) Pub Date : 2024-02-13 Varney, M. J., Benovic, J. L.
Type 2 diabetes (T2D) mellitus has emerged as a major global health concern that has accelerated in recent years due to poor diet and lifestyle. Afflicted individuals have high blood glucose levels that stem from the inability of the pancreas to make enough insulin to meet demand. Although medication can help to maintain normal blood glucose levels in individuals with chronic disease, many of these
-
Protecting Human and Animal Health: The Road from Animal Models to New Approach Methods Pharmacol. Rev. (IF 19.3) Pub Date : 2024-02-13 Kaplan, B. L. F., Hoberman, A. M., Slikker, W., Smith, M. A., Corsini, E., Knudsen, T. B., Marty, M. S., Sobrian, S. K., Fitzpatrick, S. C., Ratner, M. H., Mendrick, D. L.
Animals and animal models have been invaluable for our current understanding of human and animal biology, including physiology, pharmacology, biochemistry, and disease pathology. However, there are increasing concerns with continued use of animals in basic biomedical, pharmacological, and regulatory research to provide safety assessments for drugs and chemicals. There are concerns that animals do not
-
Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes Pharmacol. Rev. (IF 19.3) Pub Date : 2024-03-01 K.T. Babalola, M. Arora, R. Ganugula, S.K. Agarwal, C. Mohan, M.N.V. Ravi Kumar, Francesca Levi-Schaffer
The role of advanced drug delivery strategies in drug repositioning and minimizing drug attrition rates, when applied early in drug discovery, is poised to increase the translational impact of various therapeutic strategies in disease prevention and treatment. In this context, drug delivery to the lymphatic system is gaining prominence not only to improve the systemic bioavailability of various pharmaceutical
-
Emergence of Extracellular Vesicles as “Liquid Biopsy” for Neurological Disorders: Boom or Bust Pharmacol. Rev. (IF 19.3) Pub Date : 2024-03-01 Ashish Kumar, Michael A. Nader, Gagan Deep, Andrew Baker
-
A 25-Year Journey as Author and Associate Editor of Pharmacological Reviews-Editorial. Pharmacol. Rev. (IF 19.3) Pub Date : 2024-02-13 Martin C Michel
-
The SLC6A15–SLC6A20 Neutral Amino Acid Transporter Subfamily: Functions, Diseases, and Their Therapeutic Relevance Pharmacol. Rev. (IF 19.3) Pub Date : 2024-01-01 Jędrzej Kukułowicz, Krzysztof Pietrzak-Lichwa, Klaudia Klimończyk, Nathalie Idlin, Marek Bajda, Habibeh Khoshbouei
-
Halogenated Antimicrobial Agents to Combat Drug-Resistant Pathogens Pharmacol. Rev. (IF 19.3) Pub Date : 2024-01-01 Olajide Sunday Faleye, Bharath Reddy Boya, Jin-Hyung Lee, Inho Choi, Jintae Lee, Clive Page
-
Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin Pharmacol. Rev. (IF 19.3) Pub Date : 2024-01-01 Anagha Gogate, Jordyn Belcourt, Milan Shah, Alicia Zongxun Wang, Alexis Frankel, Holly Kolmel, Matthew Chalon, Prajith Stephen, Aarush Kolli, Sherouk M. Tawfik, Jing Jin, Raman Bahal, Theodore P. Rasmussen, José E. Manautou, Xiao-bo Zhong, Grace Guo
-
Nonhormonal Male Contraceptive Development--Strategies for Progress Pharmacol. Rev. (IF 19.3) Pub Date : 2023-12-15 Nickels, L., Yan, W.
Despite the widely demonstrated public health benefits of contraception, limited contraceptive options are available for men, placing both the contraceptive burden and opportunity solely on women. This review outlines the need for an increased focus on male contraceptive development and highlights several related topics, including the perspectives of women and men on male contraceptives, historical
-
Regulation of Pain Perception by Microbiota in Parkinson Disease Pharmacol. Rev. (IF 19.3) Pub Date : 2024-01-01 Zulmary Manjarres, Margarita Calvo, Rodrigo Pacheco, Habibeh Khoshbouei
-
Pharmacological Reviews’75th Year Anniversary: Past and Future—Editorial Pharmacol. Rev. (IF 19.3) Pub Date : 2024-01-01 Lynette C. Daws
-
Correction to "Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years". Pharmacol. Rev. (IF 19.3) Pub Date : 2023-12-15
-
Correction to "Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments". Pharmacol. Rev. (IF 19.3) Pub Date : 2023-12-15
-
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023 Pharmacol. Rev. (IF 19.3) Pub Date : 2023-11-01 Thomas P. Burris, Ian Mitchelle S. de Vera, Isabelle Cote, Colin A. Flaveny, Udayanga S. Wanninayake, Arindam Chatterjee, John K. Walker, Nickolas Steinauer, Jinsong Zhang, Laurel A. Coons, Kenneth S. Korach, Derek W. Cain, Anthony N. Hollenberg, Paul Webb, Douglas Forrest, Anton M. Jetten, Dean P. Edwards, Sandra L. Grimm, Sean Hartig, Carol A. Lange, Jennifer K. Richer, Carol A. Sartorius, Marc Tetel
The NR superfamily comprises 48 transcription factors in humans that control a plethora of gene network programs involved in a wide range of physiologic processes. This review will summarize and discuss recent progress in NR biology and drug development derived from integrating various approaches, including biophysical techniques, structural studies, and translational investigation. We also highlight
-
Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor Pharmacol. Rev. (IF 19.3) Pub Date : 2023-11-01 Yuesheng Zhang, Michael Gottesman
-
Lymphocyte Depleting and Modulating Therapies for Chronic Lung Allograft Dysfunction Pharmacol. Rev. (IF 19.3) Pub Date : 2023-11-01 Saskia Bos, Pauline Pradère, Hanne Beeckmans, Andrea Zajacova, Bart M. Vanaudenaerde, Andrew J. Fisher, Robin Vos, Clive Page
Chronic lung rejection, also called chronic lung allograft dysfunction (CLAD), remains the major hurdle limiting long-term survival after lung transplantation, and limited therapeutic options are available to slow the progressive decline in lung function. Most interventions are only temporarily effective in stabilizing the loss of or modestly improving lung function, with disease progression resuming
-
Therapeutic Potential of Targeting Prokineticin Receptors in Diseases Pharmacol. Rev. (IF 19.3) Pub Date : 2023-11-01 Martina Vincenzi, Amin Kremić, Appoline Jouve, Roberta Lattanzi, Rossella Miele, Mohamed Benharouga, Nadia Alfaidy, Stephanie Migrenne-Li, Anumantha G. Kanthasamy, Marimelia Porcionatto, Napoleone Ferrara, Igor V. Tetko, Laurent Désaubry, Canan G. Nebigil, Rhian Touyz
-
Effects of Medications on Heat Loss Capacity in Chronic Disease Patients: Health Implications Amidst Global Warming Pharmacol. Rev. (IF 19.3) Pub Date : 2023-11-01 Jericho Wee, Xiang Ren Tan, Samuel H. Gunther, Mohammed Ihsan, Melvin Khee Shing Leow, Doreen Su-Yin Tan, Johan G. Eriksson, Jason Kai Wei Lee, Lynette Daws
-
Optical Approaches for Investigating Neuromodulation and G Protein–Coupled Receptor Signaling Pharmacol. Rev. (IF 19.3) Pub Date : 2023-11-01 David J. Marcus, Michael R. Bruchas, Gunnar Schulte
-
Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments Pharmacol. Rev. (IF 19.3) Pub Date : 2023-10-17 Barrett, J. E., Shekarabi, A., Inan, S.
Oxycodone, a semisynthetic derivative of naturally occurring thebaine, an opioid alkaloid, has been available for more than 100 years. Although thebaine cannot be used therapeutically due to the occurrence of convulsions at higher doses, it has been converted to a number of other widely used compounds that include naloxone, naltrexone, buprenorphine, and oxycodone. Despite the early identification
-
Extracellular Vesicle Heterogeneity and Its Impact for Regenerative Medicine Applications Pharmacol. Rev. (IF 19.3) Pub Date : 2023-08-14 van de Wakker, S. I., Meijers, F. M., Sluijter, J. P. G., Vader, P.
Extracellular vesicles (EVs) are cell-derived membrane-enclosed particles that are involved in physiologic and pathologic processes. EVs are increasingly being studied for therapeutic applications in the field of regenerative medicine. Therapeutic application of stem cell–derived EVs has shown great potential to stimulate tissue repair. However, the exact mechanisms through which they induce this effect
-
Hepatic Bile Formation: Developing a New Paradigm Pharmacol. Rev. (IF 19.3) Pub Date : 2023-08-14 Javitt, N. B.
In 1959, Ivar Sperber contrasted bile formation with that of urine and proposed that water flow into the canalicular conduit is in response to an osmotic, not a hydrostatic, gradient. Early attempts to support the hypothesis using a bile acid, sodium taurocholate, and the hormone secretin to stimulate bile flow led to conflicting data and a moratorium on attempts to further develop the initial proposal
-
The Myc Family and the Metastasis Suppressor NDRG1: Targeting Key Molecular Interactions with Innovative Therapeutics Pharmacol. Rev. (IF 19.3) Pub Date : 2023-08-14 Deng, Z., Richardson, D. R.
Cancer is a leading cause of death worldwide, resulting in ~10 million deaths in 2020. Major oncogenic effectors are the Myc proto-oncogene family, which consists of three members including c-Myc, N-Myc, and L-Myc. As a pertinent example of the role of the Myc family in tumorigenesis, amplification of MYCN in childhood neuroblastoma strongly correlates with poor patient prognosis. Complexes between
-
Paradoxes of Cellular SUMOylation Regulation: A Role of Biomolecular Condensates? Pharmacol. Rev. (IF 19.3) Pub Date : 2023-08-14 Cheng, X., Yang, W., Lin, W., Mei, F.
Protein SUMOylation is a major post-translational modification essential for maintaining cellular homeostasis. SUMOylation has long been associated with stress responses as a diverse array of cellular stress signals are known to trigger rapid alternations in global protein SUMOylation. In addition, while there are large families of ubiquitination enzymes, all small ubiquitin-like modifiers (SUMOs)